-
Mashup Score: 2
SERENA-1 (NCT03616587) is a Phase 1, multi-part, open-label study of camizestrant in pre- and post-menopausal women with ER+, HER2− advanced breast cancer. Parts A and B aim to determine the safety and tolerability of camizestrant monotherapy and define doses for clinical evaluation. Patients and Methods Women aged 18 years or older with metastatic or recurrent ER+, HER2− breast cancer, refractory (or intolerant) to therapy were assigned 25 mg up to 450 mg once daily (QD; escalation) or 75, 150, or 300 mg QD (expansion).
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7
Dr. Parker and colleagues report in the current issue of Annals of Oncology the updated results of the RADICALS-RT randomized trial evaluating the superiority of adjuvant radiotherapy (ART) versus early salvage radiotherapy (eSRT).1 Based on the similar biochemical control results reported after a median follow-up of 4.9 years, eSRT was deemed by many as the standard of care for predominately clinically intermediate-risk men post-radical prostatectomy (RP). 2
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 19
In MONARCH 2, the addition of abemaciclib to fulvestrant significantly improved both progression-free survival (PFS) and overall survival (OS) in patients with HR+, HER2- advanced breast cancer (ABC) with disease progression on prior endocrine therapy (ET). In MONARCH 3, the addition of abemaciclib to a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for HR+, HER2- ABC significantly improved PFS. Here, we present the prespecified final OS results for MONARCH 3.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12MITO END-3: Efficacy of Avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy - 10 day(s) ago
Immunotherapy combined with chemotherapy significantly improves progression-free survival compared to first-line chemotherapy alone in advanced endometrial cancer, with a much larger effect size in microsatellite-instability high (MSI-H) cases. New biomarkers might help to select patients that may have benefit among those with a microsatellite-stable (MSS) tumor.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 29
Programmed cell death protein 1(PD-1) axis blockade has become the mainstay in the treatment of recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC). PD-L1 is the only approved biomarker for patient selection; however, response rate is limited even among high expressors. Our primary objective was to investigate the association of immune-cell-related biomarkers in the tumor and tumor microenvironment with PD-1 checkpoint inhibitors’ outcomes in patients with R/M HNSCC.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
In this Article of the month podcast, Annals of Oncology Editor in Chief Tom Powles talks to Prof. Amanda Psyrri, of the National Kapodistrian University of Athens, Greece. They discuss herrecently p
Source: soundcloud.comCategories: General Medicine News, Onc News and JournalsTweet-
The Annals of Oncology article of the month ⭐️podcast 🎙️is now available! EiC @tompowles1 discusses with @amanda_psyrri the association of immune biomarkers and patient outcome in HNSCC treated with Nivolumab Soundcloud: https://t.co/MJdEXU85FN Spotify: https://t.co/9lFJ9XrBFt https://t.co/d8bUsI149L
-
-
Mashup Score: 27Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047] - 1 month(s) ago
Long-term results from RADICALS-RT confirm adjuvant RT after radical prostatectomy increases the risk of urinary and bowel morbidity, but does not meaningfully improve disease control. An observation policy with salvage RT for PSA failure should be the current standard after radical prostatectomy.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Oncogenic extrachromosomal DNA identification using whole-genome sequencing from formalin-fixed glioblastomas - 2 month(s) ago
Glioblastoma, an area of urgent unmet clinical need, is the most common intrinsic brain cancer and frequently contains extrachromosomal DNA (ecDNA). EcDNA is increasingly recognized as a driver of cancer evolution and a mediator of therapy resistance1,2. Recent studies have implicated ecDNA as a prognostic marker across many cancer types, and a driver of glioblastoma, with emerging clinical trials aiming to leverage knowledge of ecDNA status or therapeutically target ecDNA directly3.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 36Response-guided neoadjuvant sacituzumab govitecan for localized triple negative breast cancer: results from the NeoSTAR trial - 2 month(s) ago
Sacituzumab govitecan (SG), a novel antibody-drug conjugate targeting Trop2, is approved for pre-treated metastatic triple negative breast cancer (mTNBC). We conducted an investigator-initiated clinical trial evaluating neoadjuvant (NA) SG (NCT04230109), and report primary results
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14Response-guided neoadjuvant sacituzumab govitecan for localized TNBC - 2 month(s) ago
Sacituzumab govitecan (SG), a novel antibody–drug conjugate (ADC) targeting TROP2, is approved for pre-treated metastatic triple-negative breast cancer (mTNBC). In this podcast, Annals of Oncology Edi
Source: soundcloud.comCategories: General Medicine News, Onc News and JournalsTweet-
🆕The latest Annals of Oncology article of the month podcast 🎙️ is out. EiC @tompowles1 discusses with @dradityabardia the NeoSTAR trial investigating Sacituzumab Govitecan in the pre-operative setting of TNBC Soundcloud: https://t.co/H96dU2RC4l Spotify: https://t.co/eYntXN63Tv https://t.co/3o8yWAM5Ox
-
#OpenAccess in Annals of Oncology, @ErikaHamilton9 and coll. report on the monotherapy results from the SERENA-1 study investigating next-generation oral SERD camizestrant in ER+, HER2- advanced breast cancer https://t.co/IrmYvFyNoI #bcsm